Regardless of the uncertainty surrounding the upcoming budget and user fee negotiations, the Center for Biologics Evaluation and Research (CBER) will make the implementation of the 21st Century Cures Act's regenerative medicines provisions a major priority, center Director Peter Marks says.
"At the moment, we are reasonably well-resourced … I think just as Dr. [Janet] Woodcock in CDER was able to...








